Effect of Interleukin-3 on Responsiveness to Granulocyte-Colony-stimulating Factor in Severe Aplastic Anemia
- Klaus Geissler, MD;
- Christa Forstinger, MD;
- Peter Kalhs, MD;
- Paul Knöbl, MD;
- Peter Kier, MD;
- Paul Kyrle, MD; and
- Klaus Lechner, MD
Excerpt
Some patients with aplastic anemia show temporary improvements in hematopoiesis after monotherapy with hematopoietic growth factors (1-3), but those with severe cases rarely respond (4). Inadequate response in these patients is thought to be caused by a profound deficiency of hematopoietic progenitors (5). We recently reported that interleukin-3 effectively expands the pool of hematopoietic progenitors in primates, suggesting that this molecule may be used therapeutically to make hematopoiesis more responsive to late-acting cytokines (6). Pretreatment with interleukin-3 has been shown to potentiate the effects of granulocyte-macrophage colony-stimulating factor on myelopoiesis (7), of erythropoietin on erythropoiesis (8), and of interleukin-6 on
This 100-word excerpt has been provided in the absence of an abstract.
Acknowledgments
Acknowledgment: The authors thank Eva Kabrna for technical assistance.
Article and Author Information
-
From the University of Vienna, Vienna, Austria. For current author addresses, see end of text.
-
Requests for Reprints: Klaus Geissler, MD, First Clinic of Internal Medicine, University of Vienna, Währingergürtel 18-20, A-1090 Vienna, Austria.
-
Current Author Addresses: Drs. Geissler, Forstinger, Kalhs, Knöbl, Kier, Kyrle, and Lechner: First Clinic of Internal Medicine, University of Vienna, Währingergürtel 18-20, A-1090 Vienna, Austria.
Most Read
